An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new guidance from the American Psychological Association offers advice to therapists about patients who are using GLP-1 drugs. These drugs — famous names like Ozempic and Wegovy — are changing how people manage weight and some mental-health issues. The APA is trying to help therapists understand how patients might be affected and what to consider in therapy sessions. GLP-1 stands for “glucagon-like peptide-1,” which is a type of small protein our bodies make that helps control appetite and blood sugar. The medicines called GLP-1 receptor agonists (that’s a fancy way of saying “drugs that act like this natural protein”) mimic that signal. In plain terms, they can make people feel less hungry, slow how fast the stomach empties, and change how the body handles glucose. These effects are why they’re used for diabetes and, more recently, for helping with weight loss. The APA guidance is not a brand-new study with fresh clinical data. Instead, it reviews what therapists need to know about patients who are on these drugs. It highlights concerns such as changes in body image, grief or anxiety around weight loss, and how medication use may interact with eating-disorder treatment or other mental-health care. The document draws on existing research and clinical experience rather than reporting a single large trial. So it’s about practical, clinical judgment rather than proving new medical effects. This matters because many people seeing psychologists or counselors are now taking GLP-1 drugs, and those medicines can affect emotions, identity, and behavior. Therapists might need to adjust their approach, ask about medication use, coordinate with medical providers, and watch for shifts in mood or disordered eating patterns. For patients, it means your therapist should be aware of your medication and consider it part of the picture, especially if you’re losing weight, changing eating habits, or feeling distressed about body changes. There are important caveats. The APA guidance is not medical advice on whether to start or stop medication; that remains a job for doctors and specialists. GLP-1 drugs have documented side effects like nausea and gastrointestinal discomfort, and their long-term mental-health effects are still being studied. They may not be appropriate for people with certain eating disorders, and stopping them can lead to weight regain, which can be emotionally difficult. Therapists and patients should communicate with prescribing clinicians to manage risks and monitor symptoms. Bottom line: The APA is urging therapists to learn about GLP-1 medications and to consider them when planning care, because these drugs can affect more than just the body — they can influence thoughts, feelings, and relationships with food.
Source: American Psychological Association (APA)